SUPPLEMENTARY TABLE 1. Vaccine effectiveness* of bivalent compared with effectiveness of original monovalent vaccination against COVID-19-related thromboembolic events† among Medicare beneficiaries aged ≥65 years with immunocompromise§ and beneficiaries aged ≥18 years with end stage renal disease receiving dialysis¶ with immunocompromise, by age group and time since vaccination — United States, September 2022–March 2023
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

SUPPLEMENTARY TABLE 1. Vaccine effectiveness* of bivalent compared with effectiveness of original monovalent vaccination against COVID-19-related thromboembolic events† among Medicare beneficiaries aged ≥65 years with immunocompromise§ and beneficiaries aged ≥18 years with end stage renal disease receiving dialysis¶ with immunocompromise, by age group and time since vaccination — United States, September 2022–March 2023

Filetype[PDF-170.67 KB]


English
Details Related Documents You May Also Like

Details:

Supporting Files

  • No Additional Files
More +

Related Documents

You May Also Like

Checkout today's featured content at stacks.cdc.gov